5 Best Biotech Stocks Under $20 in Cathie Wood’s Portfolio

Page 5 of 5

1. Evogene Ltd. (NASDAQ:EVGN)

Number of Hedge Fund Holders: 6

Share price as of November 24: $2.02

Evogene Ltd. (NASDAQ:EVGN) is a computational biology company based in Israel. The company develops a Computational Predictive Biology (CPB) platform used in cancer drug discovery. The CPB platform has also agriculture and industrial application. 

In October, Evogene Ltd.’s (NASDAQ:EVGN) subsidiary, Canonic, launched its medical marijuana products. Roth Capital analyst Brian Wright highlighted the company’s medical cannabis commercialization and initiated a Buy rating on Evogene Ltd. (NASDAQ:EVGN) with a $7 price target. 

At the end of the third quarter of 2021, 6 hedge funds in the database of Insider Monkey held stakes worth $13 million in Evogene Ltd. (NASDAQ:EVGN), compared to 7 in the previous quarter worth $18 million.

Cathie Wood’s ARK Investment Management is the leading stakeholder of the biotech company. Latest filings show that ARK Investment Management owned over 4 million shares of Evogene Ltd. (NASDAQ:EVGN) at the end of the third quarter of 2021 worth $10.6 million, representing 0.02% of the portfolio. 

You can also take a peek at Amit Nitin Doshi’s Harbor Spring Capital Portfolio: Top 10 Stock Picks and Why These 10 Stocks Trended This Week.

Page 5 of 5